Showing 6451-6460 of 10150 results for "".
- Practical Dermatology Magazine Mourns the Passing of Two Preeminent Dermatologistshttps://practicaldermatology.com/news/practical-dermatology-mourns-the-passing-of-two-preeminent-dermatologists/2460741/By Wendy Lewis It is with great sadness that Practical Dermatology® magazine pays our respects to two very talented and respected dermatologists, Melanie Grossman, MD and Marta Rendon, MD.
- About Three-Quarters of Americans Wish They Had Taken Better Care of Themselves During the Pandemichttps://practicaldermatology.com/news/about-three-quarters-of-americans-wish-they-had-taken-better-care-of-themselves-during-the-pandemic/2460732/Seventy-four percent of people say they wish they’d taken better care of themselves this past year, including many admitting to sub-par skincare and grooming, finds a new survey of more than 2,022 people by
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- Cetaphil Launches Sensitive Skin Awareness Weekhttps://practicaldermatology.com/news/cetaphil-launches-sensitive-skin-awareness-week/2460720/Happy Sensitive Skin Awareness Week! Sponsored by Cetaphil, the weeklong program kicks off on March 22nd and runs through March 28th. It will feature a lineup of dermatologists, influencers, and experts who wil
- Snacking on Almonds May Smooth Wrinkles, Reduce Dark Spotshttps://practicaldermatology.com/news/snacking-on-almonds-may-smooth-wrinkles-reduce-dark-spots/2460717/Snacking on almonds may help reduce wrinkles and skin pigmentation in postmenopausal women, according to a new study funded by the Almond Board of California. In this 6-month randomized controlled trial, 49 healthy postmenopausal women with Fitzpatrick skin type 1 or 2 were randomly ass
- Vyne Therapeutics to Move Forward with Topical Tofacitinib/Fingolimod Gel for ADhttps://practicaldermatology.com/news/vyne-therapeutics-to-move-forward-with-topical-tofacitinibfingolimod-gel-for-ad/2460707/Vyne Therapeutics Inc. plans to move forward on development of its fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical gel for mild-to-moderate atopic dermatitis. A phase 2a proof of concept study for FMX114 is planned to start
- With sNDA, Amgen Seeks Approval for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/with-snda-amgen-seeks-approval-for-otezla-in-mild-to-moderate-pso/2460700/Amgen has submitted a supplemental New Drug Application (sNDA) to the FDA for Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The sNDA is based on data from the Phase 3 ADVANCE trial tha
- Label Update: Simponi Aria Improves Fatigue in PsA, RAhttps://practicaldermatology.com/news/label-update-simponi-aria-improves-fatigue-in-psa-ra/2460699/Simponi Aria (golimumab) from Janssen Pharmaceutical Company of Johnson & Johnson is the first and only fully human anti-tumor necrosis factor (TNF) biologic approved by the FDA to include language in its product label stating that the treatment results in improvement in fatigue for adul
- AbbVie, Evolus Agree to Settlementhttps://practicaldermatology.com/news/abbvie-evolus-agree-to-settlement/2460697/AbbVie, Evolus, and Medytox have agreed to a new settlement to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be